![Leonid Beigelman](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Leonid Beigelman
Nessuna posizione attualmente
Patrimonio netto: 528 623 $ in data 30/06/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Lawrence Blatt | M | 62 |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA.
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 26 anni |
K. Hirth | M | 72 |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 6 anni |
Carole Nüchterlein | F | 62 | 6 anni | |
Jim Scopa | M | 65 | 3 anni | |
Jennifer Doudna | M | 60 | 6 anni | |
Mary Beckerle | M | 69 | 9 anni | |
Bridget Martell | M | 58 | 3 anni | |
Julian Symons | M | 63 |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 14 anni |
Sushmita M. Chanda | M | 58 |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 14 anni |
William Cohn | M | 64 | 6 anni | |
Lesley Calhoun | F | 58 | 4 anni | |
Regina Barzilay | M | - | 6 anni | |
Paul Ruh | M | - | 7 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Jack Nielsen | M | 60 |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 13 anni |
Howard Robin | M | 71 |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 5 anni |
Lucinda Quan | F | 51 |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 9 anni |
John R. Donovan | M | - |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | - |
John Fry | M | - |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 12 anni |
Chris Christoffersen | M | 86 |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 10 anni |
John C. Hodgman | M | 69 | - | |
Rosanne Roth | F | - |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 5 anni |
Martin Madden | M | 64 | 31 anni | |
Christopher DelOrefice | M | 52 | 4 anni | |
Thomas Woiwode | M | 52 | 5 anni | |
Lars Ekman | M | 74 | 7 anni | |
Peter Moldt | M | 65 | - | |
Patti Ketchner | F | - |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 13 anni |
Matthew McClure | M | 53 |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 12 anni |
Kathleen Glaub | F | 70 | - | |
David Kabakoff | M | 76 | 9 anni | |
Nassim Usman | M | 64 |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 13 anni |
Louis C. Drapeau | M | 79 | 7 anni | |
James Cullen | M | 81 | 20 anni | |
Gregory T. Sloma | M | 71 |
Transgenomic, Inc.
![]() Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 6 anni |
Leo Mullin | M | 81 | 16 anni | |
Michael Draper | M | 58 |
Transgenomic, Inc.
![]() Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | 4 anni |
Patricia P. Ketchner | F | - |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 13 anni |
Mary Coleman | M | 80 | 13 anni | |
Denice Torres | F | 64 | 12 anni | |
Paul McKenzie | M | 58 | 1 anni | |
Deeptha Khanna | F | 48 | 5 anni | |
Nimi Srivastava Meschke | F | 50 | 4 anni | |
Daniel Scavilla | M | 59 | 3 anni | |
Donna Godward | F | 69 | 6 anni | |
Adam Hacker | M | 55 | 10 anni | |
Michael McBreen | M | 58 | 1 anni | |
Peter Shen | M | - | 5 anni | |
Charlotte Simonelli | F | 52 | - | |
Valerie Asbury | F | 64 | 5 anni | |
Chris Picariello | M | - | 2 anni | |
Alicia Sontag | F | - | 4 anni | |
Widya Mulyasasmita | M | - | 3 anni | |
Patrick McCrummen | M | - | - | |
KULDEEP NEOTE | M | - | 1 anni | |
Brian Imszennik | M | - | 6 anni | |
Mai Jing Liao | M | 54 | 3 anni | |
Patrick Brady | M | - | 18 anni | |
Yana Ignatova | F | - | - | |
JD Moore | M | 51 | 2 anni | |
Sunny Lee Ryan | F | 54 |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 1 anni |
Elizabeth McCombs | F | 48 | 3 anni | |
Chris Calabretta | M | - | 26 anni | |
Roberto di Bernardini | M | 60 | 9 anni | |
Michelle Turner | F | 50 | - | |
Robert Wills | M | 70 | 26 anni | |
Pamela A. Pavco | M | 67 |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 4 anni |
Hans Melotte | M | - | 6 anni | |
Mark Egan | M | - |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 5 anni |
Roger L. Hawley | M | 71 | 3 anni | |
Bharatt Chowrira | M | 59 |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 13 anni |
Cynthia Y. Robinson | M | 65 | 3 anni | |
Russell T. Kawahata | M | - | 4 anni | |
Kathleen Widmer | F | 62 | 8 anni | |
Lawrence E. Bullock | M | 67 |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 7 anni |
William Halter | M | 63 | 4 anni | |
Rowan Chapman | M | 53 | 2 anni | |
Kent Alan Gossett | M | - |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | - |
Heath Lukatch | M | 56 |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | 5 anni |
Chandra Vargeese | M | 63 |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 8 anni |
Euan Stuart Thomson | M | 60 | 2 anni | |
Dale Schwartz | M | 63 |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 5 anni |
Regev Yativ | M | - | 1 anni | |
Louise Mehrotra | F | - | 11 anni | |
Peter Haeberli | M | - |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | - |
Jorge Mesquita | M | 61 | 5 anni | |
Tomas Jan Heyman | M | 68 | 23 anni | |
Maggie FitzPatrick | F | 58 | 3 anni | |
Minnie Baylor-Henry | F | 76 | 4 anni | |
Partha P. Ray | M | - | 4 anni | |
Anil Kapur | M | 54 | 11 anni | |
Carol Brosgart | M | 72 |
Alios BioPharma, Inc.
![]() Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | - |
Stephen J. Cosgrove | M | - | 41 anni | |
John A. Papa | M | - | - | |
Mark Litton | M | 56 |
Sirna Therapeutics, Inc.
![]() Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | 2 anni |
Gary Pruden | M | 62 | 32 anni | |
Thomas J. Spellman | M | 59 | - | |
David Elkins | M | 55 | 4 anni | |
Bruce W. Tomlinson | M | 64 | 5 anni | |
Gary Fischetti | M | 63 | 2 anni | |
Laurent Metz | M | - | 7 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 100 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Leonid Beigelman
- Contatti personali